Designing of Molecular Glues 2022 London United Kingdom
Hetero-bifunctional protein degraders like proteolysis targeting chimeras (PROTACs) have found their way into the clinic by utilizing the body’s natural disposal system to tag and degrade unwanted proteins implicated in various diseases. These degraders are large molecules consisting of a E3 binding ligand and a ligand binding the target protein, coupled together by a linker. On the other hand, monovalent degraders or molecular glues consist of a single degrader molecule that attaches to both the E3 ligase and target protein and tend to be smaller and more drug-like. These glues have been discovered serendipitously in the past, however recently, there are efforts being made to try and design them more rationally. Cambridge Healthtech Institute’s inaugural virtual conference discusses some of these innovative design strategies and screening methods to discover and optimize molecular glues for therapeutic purposes. The conference features live talks given by experts and includes online discussions for active networking and idea-generation.
